Abstract
Adagrasib is a KRASG12C inhibitor selected for favorable properties, including long half-life (∼24 h), dose-dependent PK, and CNS penetration; it has demonstrated clinical activity in patients (pts) with KRASG12C NSCLC (ORR 43%; median OS 12.6 months), including in pts with CNS metastases (intracranial ORR per mRANO-BM criteria 33%).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
